UA137816U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, including clinical examination, radiography, according to a useful model in addition to the serum of the patient determine the polymorphism of genes of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T7NU) , C-reactive protein (PSP), interleukin 6 (IL-6), homocysteine and homozygous carrier 677-TT, 786-CC and thrombomodulin levels> 5 ng / ml, TGF-T1 <14 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis were chosen as the closest analogue. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N. Okorokov. Diagnostics of diseases of internal organs. M., 2001. - vol. 2. - p. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEK) is determined in the patient's blood serum

C677T), nitric oxide synthase (MOH T786C), content of thrombomodulin, transforming growth factor beta 1 (TGF-VI1), C-reactive protein (CRP), interleukin 6 (IL-6), homocysteine. With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, TGF-VI "14 ng/ml,

SRP »6 mg/l, IL-6 »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, an X-ray is taken, the polymorphism of MTNEK C677tT, eMmo5 T786C genes is determined, the content of thrombomodulin, TGF-B1, SRP, IL-6, and homocysteine is determined by the immunoenzymatic method. With homozygous carriers of 677-TtT, 786-SS, levels of thrombomodulin "5 ng/ml, TFR-DVI1 "14 ng/ml, SRP "6 mg/l, IL-6 "10 ng/l, homocysteine 220 μmol/l are predicted development of osteoarthritis.

A specific example of using the method.

Patient K., 60 years old, was admitted to the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEK C677T and emo5 T786C genes were determined in blood serum. The content of thrombomodulin, TGF-B1, SRP, IL-b6, and homocysteine was determined by immunoenzymatic method. A homozygous carrier of 677-T1 and 786-СС was established, thrombomodulin levels - 12 ng/ml, TFR-B1-9 ng/ml, SRP 16 mg/l, IL-b6 25 ng/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEK С677Т), nitric oxide synthase (6eMO5 T786С), the content of thrombomodulin, transforming growth factor beta 1 (TGF- DRI), C-reactive protein (SRP), interleukin 6 (IL-6), homocysteine and with homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, TGF-DVI "14 ng/ml, SRP »b mg/l, IL-6 »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.